Image of the Hawkeye Chrono live-cell imaging system, supplied by Curiosys as an ODM product under the Revvity brand / Provided by Curiosis

Curiosis, a lab automation specialist, is significantly expanding its partnership with global life sciences giant Revvity, boosting their supply contract to a whopping 110 billion KRW (approximately 72.8 million USD).

The company announced on Monday that it has broadened its original design manufacturer (ODM) supply agreement with Revvity for cutting-edge live cell imaging systems. The deal covers China, including Hong Kong and Macau, and extends through March 31, 2029.

The contract's total value, roughly 110 billion KRW (approximately 72.8 million USD), dwarfs Curiosis's projected 2025 revenue of 68 billion KRW (approximately 45 million USD) by 160%. This substantial amount will be realized as revenue through future purchase orders.

This latest agreement revamps the August 2025 contract, introducing quarterly minimum order quantities (MOQs) and a longer term. These changes are set to enhance supply predictability and boost production responsiveness. The first MOQ shipment is slated for April 1, 2026.

At the heart of this deal is the Hawkeye Chrono, a high-throughput screening (HTS) live cell imaging system developed and supplied by Curiosis as an ODM product.

This revolutionary system can simultaneously analyze about 600 organoids within an incubator, making it a game-changer for organoid analysis, drug discovery, and cell therapy development.

Curiosis is committed to further expanding its collaborations with global partners in the rapidly growing organoid and cell-based high-throughput analysis market.

A Curiosis spokesperson emphasized the significance of this partnership, stating that by integrating the products into the global partners' portfolios, it's not just securing supply channels, it's diversifying the pathways into international markets. The company aims to grow both its direct sales through the Celloger® brand and its ODM revenue via global partnerships.

Curiosis is a key player in the bio-materials, parts, and equipment sector, providing crucial automation tools for drug development and cell therapy production.

Their flagship product, Celloger, enables real-time monitoring and analysis of cell cultivation within incubators. To date, over 420 Celloger units have been deployed across 29 countries.

The company's competitive edge stems from its 100% in-house development of core components. By mastering the production of critical elements like circuit boards, image sensors, and optomechatronics, Curiosis uniquely positions itself as both a parts supplier and a finished product manufacturer.

Curiosis, a lab automation specialist, is significantly expanding its partnership with glo …

Curiosis Expands Revvity Partnership With 110 Billion KRW Supply Deal for Live-Cell Imaging Systems